Pretransplant patient and disease characteristics
| . | Overall population . | P value . | PSM group . | P value . | ||
|---|---|---|---|---|---|---|
| Autopembro . | Allotransplant . | Autopembro . | Allotransplant . | |||
| (N = 20) . | (N = 112) . | (N = 19) . | (N = 63) . | |||
| Age, median (range) | 63.5 (26-75) | 55 (18-75) | .12 | 64 (26-75) | 59 (22-74) | .42 |
| Male sex | 7 (35%) | 66 (59%) | .05 | 7 (37%) | 39 (62%) | .07 |
| Race | ||||||
| Non-Hispanic White | 9 (45%) | 77 (69%) | 8 (42%) | 41 (65%) | ||
| Hispanic White | 0 (0%) | 8 (7%) | 0 (0%) | 5 (8%) | ||
| Black | 9 (45%) | 16 (14%) | .02 | 9 (48%) | 12 (19%) | .03 |
| Asian | 1 (5%) | 9 (8%) | 1 (5%) | 5 (8%) | ||
| American Indian/native Alaskan | 1 (5%) | 1 (1%) | 1 (5%) | 0 (0%) | ||
| Unknown | 0 (0%) | 1 (1%) | ||||
| KPS | ||||||
| 60-80 | 19 (95%) | 98 (87%) | .47 | 18 (95%) | 56 (89%) | .67 |
| 90 | 1 (5%) | 14 (13%) | 1 (5%) | 7 (11%) | ||
| HCT-CI | ||||||
| 0-2 | 3 (15%) | 39 (35%) | 3 (16%) | 13 (21%) | ||
| 3-5 | 14 (70%) | 53 (47%) | .14 | 14 (74%) | 39 (62%) | .75 |
| ≥6 | 3 (15%) | 20 (18%) | 2 (11%) | 11 (17%) | ||
| Patient CMV status | ||||||
| Positive | 15 (75%) | 88 (79%) | .77 | 15 (79%) | 49 (78%) | 1.00 |
| Negative | 5 (25%) | 24 (21%) | 4 (21%) | 14 (22%) | ||
| AML risk category | ||||||
| Adverse | 8 (40%) | 41 (37%) | .72 | 8 (42%) | 23 (37%) | .79 |
| Intermediate | 12 (60%) | 71 (63%) | 11 (58%) | 40 (63%) | ||
| Time from diagnosis to transplant, median (range) | 156 (94-1530) | 135.5 (67-6182) | .09 | 152 (94-1505) | 148 (72-6182) | .40 |
| Time from CR to transplant∗, median (range) | 108 (48-356) | 83.5 (20-589) | .02 | 105 (48-356) | 91 (21-589) | .18 |
| Induction | ||||||
| FLAG-ida/CLAG-ida | 10 (50%) | 84 (75%) | 10 (53%) | 44 (70%) | ||
| 7 + 3 | 6 (30%) | 14 (12%) | 5 (26%) | 8 (13%) | ||
| CPX-351 | 2 (10%) | 8 (7%) | .10 | 2 (11%) | 6 (10%) | .38 |
| FLAG | 2 (10%) | 3 (3%) | 2 (11%) | 2 (3%) | ||
| HMA/venetoclax | 0 (0%) | 2 (2%) | 0 (0%) | 2 (3%) | ||
| HMA | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Consolidation | ||||||
| HiDAC | 18 (90%) | 76 (68%) | 17 (89%) | 41 (65%) | ||
| HMA | 2 (10%) | 21 (19%) | 2 (11%) | 11 (17%) | ||
| HMA/venetoclax | 0 (0%) | 4 (3%) | .61 | 0 (0%) | 4 (6%) | .59 |
| Clo-Cy | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Vyxeos | 0 (0%) | 2 (2%) | 0 (0%) | 1 (2%) | ||
| None | 0 (0%) | 8 (7%) | 0 (0%) | 5 (8%) | ||
| Consolidation(no. of cycles), median (range) | 2 (1-7) | 1 (0-16) | .02 | 2 (1-7) | 1.5 (0-16) | .13 |
| FLT3-ITD mutated (yes) | 3 (15%) | 34 (30%) | .19 | 3 (16%) | 16 (25%) | .54 |
| FLT3-TKD (yes) | 2 (20%) | 7 (6%) | .63 | 2 (11%) | 2 (3%) | .23 |
| NPM1 (yes) | 2 (10%) | 31 (28%) | .16 | 2 (11%) | 16 (25%) | .22 |
| IDH1/2 (yes) | 6 (30%) | 27 (24%) | .58 | 6 (32%) | 13 (21%) | .36 |
| MLL (yes) | 2 (10%) | 5 (4%) | .29 | 2 (11%) | 5 (8%) | .66 |
| ASXL1/RUNX1/TP53 (yes) | 5 (25%) | 23 (21%) | .77 | 5 (26%) | 12 (19%) | .53 |
| C-KIT+ CBF (yes) | 2 (10%) | 6 (5%) | .35 | 2 (11%) | 3 (5%) | .33 |
| −7/del7q (yes) | 2 (10%) | 10 (9%) | 1.00 | 2 (11%) | 6 (10%) | 1.00 |
| Complex karyotype (yes) | 2 (10%) | 16 (14%) | 1.00 | 2 (11%) | 9 (14%) | 1.00 |
| Secondary AML (yes) | 3 (15%) | 15 (13%) | .74 | 3 (16%) | 8 (13%) | .71 |
| Therapy-related AML (yes) | 1 (5%) | 8 (7%) | 1.00 | 1 (5%) | 5 (8%) | 1.00 |
| Pretransplant status | ||||||
| CR1 | 16 (80%) | 94 (84%) | .74 | 16 (84%) | 53 (84%) | 1.00 |
| CR2/3 | 4 (20%) | 18 (16%) | 3 (16%) | 10 (16%) | ||
| MRD+at PBMT | ||||||
| Yes | 6 (30%) | 28 (25%) | 6 (32%) | 17 (27%) | ||
| No | 14 (70%) | 76 (68%) | .65 | 13 (68%) | 42 (67%) | .73 |
| Unknown | 0 (0%) | 8 (7%) | 0 (0%) | 4 (6%) | ||
| Donor type | ||||||
| AUTO | 20 (100%) | 0 (0%) | 19 (100%) | 0 (0%) | ||
| Matched related donor | 0 (0%) | 28 (25%) | < .001 | 0 (0%) | 16 (25%) | < .001 |
| MUD | 0 (0%) | 26 (23%) | 0 (0%) | 16 (25%) | ||
| HAPLO | 0 (0%) | 58 (52%) | 0 (0%) | 31 (49%) | ||
| Intensity | ||||||
| Myelo | 9 (45%) | 58 (52%) | 9 (47%) | 29 (46%) | ||
| RIC | 11 (55%) | 34 (30%) | .03 | 10 (53%) | 20 (32%) | .04 |
| Nonmyelo | 0 (0%) | 20 (18%) | 0 (0%) | 14 (22%) | ||
| Y of transplant | ||||||
| 2017-2018 | 11 (55%) | 46 (41%) | .33 | 10 (53%) | 29 (46%) | .79 |
| 2019-2021 | 9 (45%) | 66 (59%) | 9 (47%) | 34 (54%) | ||
| No. of survivors | 14 | 78 | 14 | 49 | ||
| Survivor follow-up (mo), median (range) | 36.9 (10.9-58.6) | 35.0 (13.8-70.2) | .69 | 36.9 (10.9-58.6) | 36.9 (14.1-69.2) | .80 |
| . | Overall population . | P value . | PSM group . | P value . | ||
|---|---|---|---|---|---|---|
| Autopembro . | Allotransplant . | Autopembro . | Allotransplant . | |||
| (N = 20) . | (N = 112) . | (N = 19) . | (N = 63) . | |||
| Age, median (range) | 63.5 (26-75) | 55 (18-75) | .12 | 64 (26-75) | 59 (22-74) | .42 |
| Male sex | 7 (35%) | 66 (59%) | .05 | 7 (37%) | 39 (62%) | .07 |
| Race | ||||||
| Non-Hispanic White | 9 (45%) | 77 (69%) | 8 (42%) | 41 (65%) | ||
| Hispanic White | 0 (0%) | 8 (7%) | 0 (0%) | 5 (8%) | ||
| Black | 9 (45%) | 16 (14%) | .02 | 9 (48%) | 12 (19%) | .03 |
| Asian | 1 (5%) | 9 (8%) | 1 (5%) | 5 (8%) | ||
| American Indian/native Alaskan | 1 (5%) | 1 (1%) | 1 (5%) | 0 (0%) | ||
| Unknown | 0 (0%) | 1 (1%) | ||||
| KPS | ||||||
| 60-80 | 19 (95%) | 98 (87%) | .47 | 18 (95%) | 56 (89%) | .67 |
| 90 | 1 (5%) | 14 (13%) | 1 (5%) | 7 (11%) | ||
| HCT-CI | ||||||
| 0-2 | 3 (15%) | 39 (35%) | 3 (16%) | 13 (21%) | ||
| 3-5 | 14 (70%) | 53 (47%) | .14 | 14 (74%) | 39 (62%) | .75 |
| ≥6 | 3 (15%) | 20 (18%) | 2 (11%) | 11 (17%) | ||
| Patient CMV status | ||||||
| Positive | 15 (75%) | 88 (79%) | .77 | 15 (79%) | 49 (78%) | 1.00 |
| Negative | 5 (25%) | 24 (21%) | 4 (21%) | 14 (22%) | ||
| AML risk category | ||||||
| Adverse | 8 (40%) | 41 (37%) | .72 | 8 (42%) | 23 (37%) | .79 |
| Intermediate | 12 (60%) | 71 (63%) | 11 (58%) | 40 (63%) | ||
| Time from diagnosis to transplant, median (range) | 156 (94-1530) | 135.5 (67-6182) | .09 | 152 (94-1505) | 148 (72-6182) | .40 |
| Time from CR to transplant∗, median (range) | 108 (48-356) | 83.5 (20-589) | .02 | 105 (48-356) | 91 (21-589) | .18 |
| Induction | ||||||
| FLAG-ida/CLAG-ida | 10 (50%) | 84 (75%) | 10 (53%) | 44 (70%) | ||
| 7 + 3 | 6 (30%) | 14 (12%) | 5 (26%) | 8 (13%) | ||
| CPX-351 | 2 (10%) | 8 (7%) | .10 | 2 (11%) | 6 (10%) | .38 |
| FLAG | 2 (10%) | 3 (3%) | 2 (11%) | 2 (3%) | ||
| HMA/venetoclax | 0 (0%) | 2 (2%) | 0 (0%) | 2 (3%) | ||
| HMA | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Consolidation | ||||||
| HiDAC | 18 (90%) | 76 (68%) | 17 (89%) | 41 (65%) | ||
| HMA | 2 (10%) | 21 (19%) | 2 (11%) | 11 (17%) | ||
| HMA/venetoclax | 0 (0%) | 4 (3%) | .61 | 0 (0%) | 4 (6%) | .59 |
| Clo-Cy | 0 (0%) | 1 (1%) | 0 (0%) | 1 (2%) | ||
| Vyxeos | 0 (0%) | 2 (2%) | 0 (0%) | 1 (2%) | ||
| None | 0 (0%) | 8 (7%) | 0 (0%) | 5 (8%) | ||
| Consolidation(no. of cycles), median (range) | 2 (1-7) | 1 (0-16) | .02 | 2 (1-7) | 1.5 (0-16) | .13 |
| FLT3-ITD mutated (yes) | 3 (15%) | 34 (30%) | .19 | 3 (16%) | 16 (25%) | .54 |
| FLT3-TKD (yes) | 2 (20%) | 7 (6%) | .63 | 2 (11%) | 2 (3%) | .23 |
| NPM1 (yes) | 2 (10%) | 31 (28%) | .16 | 2 (11%) | 16 (25%) | .22 |
| IDH1/2 (yes) | 6 (30%) | 27 (24%) | .58 | 6 (32%) | 13 (21%) | .36 |
| MLL (yes) | 2 (10%) | 5 (4%) | .29 | 2 (11%) | 5 (8%) | .66 |
| ASXL1/RUNX1/TP53 (yes) | 5 (25%) | 23 (21%) | .77 | 5 (26%) | 12 (19%) | .53 |
| C-KIT+ CBF (yes) | 2 (10%) | 6 (5%) | .35 | 2 (11%) | 3 (5%) | .33 |
| −7/del7q (yes) | 2 (10%) | 10 (9%) | 1.00 | 2 (11%) | 6 (10%) | 1.00 |
| Complex karyotype (yes) | 2 (10%) | 16 (14%) | 1.00 | 2 (11%) | 9 (14%) | 1.00 |
| Secondary AML (yes) | 3 (15%) | 15 (13%) | .74 | 3 (16%) | 8 (13%) | .71 |
| Therapy-related AML (yes) | 1 (5%) | 8 (7%) | 1.00 | 1 (5%) | 5 (8%) | 1.00 |
| Pretransplant status | ||||||
| CR1 | 16 (80%) | 94 (84%) | .74 | 16 (84%) | 53 (84%) | 1.00 |
| CR2/3 | 4 (20%) | 18 (16%) | 3 (16%) | 10 (16%) | ||
| MRD+at PBMT | ||||||
| Yes | 6 (30%) | 28 (25%) | 6 (32%) | 17 (27%) | ||
| No | 14 (70%) | 76 (68%) | .65 | 13 (68%) | 42 (67%) | .73 |
| Unknown | 0 (0%) | 8 (7%) | 0 (0%) | 4 (6%) | ||
| Donor type | ||||||
| AUTO | 20 (100%) | 0 (0%) | 19 (100%) | 0 (0%) | ||
| Matched related donor | 0 (0%) | 28 (25%) | < .001 | 0 (0%) | 16 (25%) | < .001 |
| MUD | 0 (0%) | 26 (23%) | 0 (0%) | 16 (25%) | ||
| HAPLO | 0 (0%) | 58 (52%) | 0 (0%) | 31 (49%) | ||
| Intensity | ||||||
| Myelo | 9 (45%) | 58 (52%) | 9 (47%) | 29 (46%) | ||
| RIC | 11 (55%) | 34 (30%) | .03 | 10 (53%) | 20 (32%) | .04 |
| Nonmyelo | 0 (0%) | 20 (18%) | 0 (0%) | 14 (22%) | ||
| Y of transplant | ||||||
| 2017-2018 | 11 (55%) | 46 (41%) | .33 | 10 (53%) | 29 (46%) | .79 |
| 2019-2021 | 9 (45%) | 66 (59%) | 9 (47%) | 34 (54%) | ||
| No. of survivors | 14 | 78 | 14 | 49 | ||
| Survivor follow-up (mo), median (range) | 36.9 (10.9-58.6) | 35.0 (13.8-70.2) | .69 | 36.9 (10.9-58.6) | 36.9 (14.1-69.2) | .80 |
Clo-Cy, clofarabine, cytarabine; CLAG-ida, cladribine, cytarabine, G-CSF, idarubicin; CMV, cytomegalovirus; FLAG-ida, fludarabine, cytarabine, G-CSF, idarubicin; HAPLO, haploidentical donor; HCT-CI, hematopoietic cell transplant comorbidity index; HiDAC, high dose cytarabine; HMA, hypomethylating agent; ITD, intertandem duplication; KPS, Karnofsky performance status; MLL, mixed lineage leukemia; MRD, measurable residual disease; auto, autologous; MUD, matched unrelated donor; Myelo, myeloablative; nonmyelo, nonmyeloablative; RIC, reduced intensity conditioning; TKD, tyrosine kinase domain; CPX-351, liposomal daunorubicin and cytarabine.
Time from CR to transplant is initiated from most recent CR before transplant.